Medical researchers have determined that targeting the endocannabinoid system with low doses of THC can stop breast cancer cells from shifting identities and spreading throughout the body. Published in Communications Biology, the study demonstrates that modulating the CB2 receptor locks tumor cells into less invasive states, presenting a new approach to combat therapy-resistant malignancies.
Cancer cells frequently display plasticity, spontaneously switching from specialized cells back into immature, stem-like states. This cellular identity switch allows tumors to evade conventional chemotherapy and radiation, which can inadvertently create evolutionary pressures that favor more aggressive, metastatic variants.
How CB2R Modulation Blocks Tumor Progression
To alter this trajectory, researchers administered an ultra-low-dose, four-day cannabinoid regimen to three-dimensional mammary tumor models and mice. They analyzed two primary receptors within the endocannabinoid system: CB1R, which handles psychoactive effects, and CB2R, which regulates inflammatory responses.
The low-dose THC exposure produced reductions in cell invasiveness, self-renewal capabilities, and tumor initiation. This response was mediated primarily by CB2R. Applying an inverse agonist named SR2, which reduces baseline CB2R activity, replicated the tumor-inhibiting effects of THC, while CB1R-targeting agents failed to produce the same outcome.
In animal models, the therapeutic impact remained stable over long durations:
- Slower Progression: Mice transplanted with THC-treated tumor organoids developed tumors later and showed slower growth for up to 100 days.
- Reduced Metastasis: Treated cells formed fewer metastatic clusters in lung tissue four weeks after injection.
- Cellular Resilience: Treated cells resisted subsequent attempts to reactivate their tumor-forming traits.
Improving Sensitivity to Standard Endocrine Drugs
Modulating CB2R also increased estrogen receptor activity within the tumor models. This molecular adjustment made the cancer cells far more responsive to tamoxifen, a common endocrine therapy used in breast cancer treatment.
Controlling this process enables "differentiated cells [to] occupy space and resources that would otherwise be used for tumor expansion," the study authors explained.
The researchers noted that "tumor cell populations occupy continuous and dynamic state landscapes, where relatively small perturbations can trigger large-scale and self-reinforcing transitions in collective behavior." Modulating CB2 receptor pathways offers a non-toxic method to reprogram tumor behavior and protect against metastatic relapse.
